ReviewViruses2023
Recent Advances in the Study of the Immune Escape Mechanism of SFTSV and Its Therapeutic Agents.
Review in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Integrative analysis of mortality risk in SFTS using machine learning and genetic approaches.mSphere · 2026Article
- Development and validation of a nomogram for predicting 30-day mortality in DBV-induced sepsis with pancreatic injury.iScience · 2026Article
- Article
- Targeting the lethal weakness of SFTSV: Latest advances in antiviral strategies and immune prevention.iScience · 2026Review
- SFTSV: a priority pathogen in need of a cure-reviewing the therapeutic.Archives of microbiology · 2026Review
- Multidimensional mechanisms of SFTSV-host interactions: viral protein functions, mFrontiers in cellular and infection microbiology · 2026Review
- Review
- Respiratory transmission potential of severe fever with thrombocytopenia syndrome bunyavirus: evidence from intranasal exposure in a humanized mouse model.Emerging microbes & infections · 2025Article
- Severe fever with thrombocytopenia syndrome virus infection induces thymic atrophy in IFNARVirulence · 2025Article
- Recent Advances in Humoral Immunity Dysregulation in Severe Fever With Thrombocytopenia Syndrome Virus (SFTSV) Infection: A Systematic Review.Health science reports · 2025Article
- Identification of Licoflavone C as a cap-dependent endonuclease inhibitor against severe fever with thrombocytopenia syndrome virus.Acta pharmacologica Sinica · 2025Article
- Advances in research on severe fever with thrombocytopenia syndrome virus.Frontiers in microbiology · 2025Review
- Platelet count and sleep quality in immune thrombocytopenia: correlation with 5-hydroxytryptamine and therapeutic implications of platelet-5-HT-melatonin axis dysregulation.Frontiers in neurology · 2025Article
- Double-Stranded RNA-Based Method for Diagnosing Severe Fever with Thrombocytopenia.Journal of clinical medicine · 2024Article
- Pathogenesis and virulence of Heartland virus.Virulence · 2024Review
- Interaction between the SFTSV envelope glycoprotein Gn and STING inhibits the formation of the STING-TBK1 complex and suppresses the NF-κB signaling pathway.Journal of virology · 2024Article
- Potent immunogenicity and neutralization of recombinant adeno-associated virus expressing the glycoprotein of severe fever with thrombocytopenia virus.The Journal of veterinary medical science · 2024Article
- ACCI could be a poor prognostic indicator for the in-hospital mortality of patients with SFTS.Epidemiology and infection · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sever fever with thrombocytopenia syndrome (SFTS) is a new infectious disease that has emerged in recent years and is widely distributed, highly contagious, and lethal, with a mortality rate of up to 30%, especially in people with immune system deficiencies and elderly patients. SFTS is an insidious, negative-stranded RNA virus that has a major public health impact worldwide. The development of a vaccine and the hunt for potent therapeutic drugs are crucial to the prevention and treatment of Bunyavirus infection because there is no particular treatment for SFTS. In this respect, investigating the mechanics of SFTS-host cell interactions is crucial for creating antiviral medications. In the present paper, we summarized the mechanism of interaction between SFTS and pattern recognition receptors, endogenous antiviral factors, inflammatory factors, and immune cells. Furthermore, we summarized the current therapeutic drugs used for SFTS treatment, aiming to provide a theoretical basis for the development of targets and drugs against SFTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.